Clinical Evaluation of a New Measles-Mumps-Rubella Trivalent Vaccine FREE

Anton J. F. Schwarz, MD; Joseph E. Jackson, MD, DrPH; N. Joel Ehrenkranz, MD; Arnoldo Ventura, PhD; Gilbert M. Schiff, MD; Vernon W. Walters, MD

[+] Author Affiliations

Received for publication Aug 30, 1974; accepted Dec 16.

Reprint requests to Biological Clinical Research Department, Dow Chemical Company, PO Box 68511, Indianapolis, IN 46268 (Dr Jackson).

Am J Dis Child. 1975;129(12):1408-1412. doi:10.1001/archpedi.1975.02120490026008.

Text Size: A A A

Published online

Article

References

Comments

ABSTRACT

ABSTRACT | REFERENCES

• In a series of clinical studies of a combined measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) vaccine, 1,481 children received the vaccine or a placebo. The vaccine did not cause any significant reactions. The frequencies of mild, transient fever or rash or both in triple-susceptible vaccinees were similar to those that follow use of Schwarz strain measles vaccine alone. Measles, mumps, and rubella seroconversion rates in triple-susceptible vaccinees ranged from 95% to 100%. Geometric mean antibody titers were as high as those that usually result from use of these same virus strains as monovalent vaccines.

(Am J Dis Child 129:1408-1412, 1975)

REFERENCES

ABSTRACT | REFERENCES

Schwarz AJF: Preliminary tests of a highly attenuated measles vaccine . Am J Dis Child 103:386-389, 1962;.

Schwarz AJF: Immunization against measles: Development and evaluation of a highly attenuated live measles vaccine . Ann Pediatr 202:241-252, 1964;.

Schwarz AJF, Anderson JT, Ramos-Alvarez M, et al: Extensive clinical evaluations of a highly attenuated live measles vaccine . JAMA 199:26-30, 1967;.

Weibel RE, Stokes J Jr, Buynak EB, et al: Live attenuated mumps-virus vaccine: 3. Clinical and serologic aspects in a field evaluation . N Engl J Med 276:245-251, 1967;.

Hilleman MR, Weibel RE, Buynak EB, et al: Live, attenuated mumps-virus vaccine: 4. Protective efficacy as measured in a field evaluation . N Engl J Med 276:252-258, 1967;.

Hilleman MR, Buynak EB, Weibel RE, et al: Live, attenuated mumps-virus vaccine . N Engl J Med 278:227-232, 1968;.

DuPan RM, Huygelen C, Peetermans J, et al: Clinical trials with a live attenuated rubella virus vaccine: Cendehill 51 strain . Am J Dis Child 115:658-662, 1968;.

Prinzie A, Huygelen C, Gold J, et al: Experimental live attenuated rubella virus vaccine: Clinical evaluation of Cendehill strain . Am J Dis Child 118:172-177, 1969;.

Kenny MT, Albright KL, Sanderson RP: Microneutralization test for the determination of mumps antibody in VERO cells . Appl Microbiol 20:371-373, 1970;.

Kenny MT, Schell KR: Microassay of measles and mumps virus and antibody in VERO cells . J Biol Standardization 3:291-306, 1975;.

Collected recommendations, Public Health Service Advisory Committee on Immunization Practices . Morbidity Mortality Weekly Rep 21( (suppl) ):11-14, 23-25, 1972;.

Kenny MT, Jackson JE: Age-related immunity to measles, mumps, and rubella in Latin American and United States children . Am J Epidemiol , to be published.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal